Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients

British Journal of Cancer

Volumn 110, Issue 1, 2014, Pages 183-188

  Szkandera, J ^a   Stotz, M ^a   Absenger, G ^a   Stojakovic, T ^a   Samonigg, H ^a   Kornprat, P ^a   Schaberl Moser, R ^a   Alzoughbi, W ^a   Lackner, C ^a   Ress, A L ^a   Seggewies, F S ^a   Gerger, A ^a   Hoefler, G ^a   Pichler, M ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

C reactive protein; pancreatic cancer; prognostic factor

Indexed keywords

C REACTIVE PROTEIN; GEMCITABINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; DISEASE SEVERITY; FEMALE; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VALIDATION STUDY;

AGED; C-REACTIVE PROTEIN; CARCINOMA, PANCREATIC DUCTAL; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84891883739     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.701     Document Type: Article

References (30)

1. Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmueller M, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A (2013) A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 109: 395-400.
2. Black S, Kushner I, Samols D. C-reactive Protein (2004) J Biol Chem 279: 48487-48490. (Pubitemid 39625721)
3. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867. (Pubitemid 36019639)
4. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) Exocrine and endocrine pancreas. In: AJCC Cancer Staging Manual. 7th edn, 241-249.
5. Springer: New York. Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ, Carter DC (1995) Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75: 2077-2082.
6. Fortner JG, Klimstra DS, Senie RT, Maclean BJ (1996) Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 223: 147-153. (Pubitemid 26065207)
7. Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR, Berry DP (2011) Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg 35: 868-872.
8. Griffanti-Bartoli F, Arnone GB, Ceppa P, Ravera G, Carrabetta S, Civalleri D (1994) Malignant tumors in the head of the pancreas and the periampullary region. Diagnostic and prognostic aspects. Anticancer Res 14: 657-666. (Pubitemid 24172188)
9. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K, Takenaka K (2005) The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103: 1856-1864. (Pubitemid 40563258)
10. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, Imrie CW (2005) Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 92: 21-23. (Pubitemid 40188430)
11. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ (2007) C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110: 1241-1247. (Pubitemid 47435594)
12. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444.
13. McMillan DC, Canna K, McArdle CS (2003) Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90: 215-219. (Pubitemid 36237897)
14. Miki C, Konishi N, Ojima E, Hatada T, Inoue Y, Kusunoki M (2004) C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci 49: 970-976. (Pubitemid 39012280)
15. Nakamura T, Grimer R, Gaston C, Francis M, Charman J, Graunt P, Uchida A, Sudo A, Jeys L (2013) The value of C-reactive protein and comorbidity in predicting survival of patients with high grade soft tissue sarcoma. Eur J Cancer 49: 377-385.
16. Niederhuber JE, Brennan MF, Menck HR (1995) The National Cancer Data Base report on pancreatic cancer. Cancer 76: 1671-1677.
17. Ozaki H, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, Nakayama T, Tsunoda T, Suzuki T, Monden M, Saitoh Y, Yamauchi H, Ogata Y (1999) The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 29: 16-22. (Pubitemid 29058554)
18. Papadoniou N, Kosmas C, Gennatas K, Polyzos A, Mouratidou D, Skopelitis E, Tzivras M, Sougioultzis S, Papastratis G, Karatzas G, Papalambros E, Tsavaris N (2008) Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res 28: 543-549. (Pubitemid 351362868)
19. Pine JK, Fusai KG, Young R, Sharma D, Davidson BR, Menon KV, Rahman SH (2009) Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 35: 605-610.
20. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 104(4): 726-734.
21. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246: 52-60. (Pubitemid 47012207)
22. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M (2003) Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 27: 324-329. (Pubitemid 36920145)
23. Sanjay P, de Figueiredo RS, Leaver H, Ogston S, Kulli C, Polignano FM, Tait IS (2012) Preoperative serum C-reactive protein levels and postoperative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. JOP 13: 199-204.
24. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
25. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, L Ress A, Kornprat P, A Zoughbi W, Seggewies FS, Lackner C, Stojakovic T, Samonigg H, Hoefler G, Pichler M (2013) Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 109(2): 416-421.
26. Sultana A, Cox T, Ghaneh P, Neoptolemos JP (2012) Adjuvant therapy for pancreatic cancer. Recent Results Cancer Res 196: 65-88.
27. Tinchon C, Hubmann E, Pichler A, Keil F, Pichler M, Rabl H, Uggowitzer M, Jilek K, Leitner G, Bauernhofer T (2013) Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol 52(6): 1231-1233.
28. Tingstedt B, Johansson P, Andersson B, Andersson R (2007) Predictive factors in pancreatic ductal adenocarcinoma: role of the inflammatory response. Scand J Gastroenterol 42: 754-759. (Pubitemid 46763583)
29. Ueno H, Okada S, Okusaka T, Ikeda M (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59: 296-301.
30. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH (2012) Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol 29(5): 3092-3100.